The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1.
HMGB1
anticancer agent
cell bioenergetics
pyruvate kinase
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Jul 2022
17 Jul 2022
Historique:
received:
01
07
2022
revised:
14
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Energy metabolism reprogramming was recently listed as a hallmark of cancer. In this process, the switch from pyruvate kinase isoenzyme type M1 to pyruvate kinase isoenzyme type M2 (PKM2) is believed to play a crucial role. Interestingly, the activity of the active form of PKM2 can efficiently be inhibited by the high-mobility group box 1 (HMGB1) protein, leading to a rapid blockage of glucose-dependent aerobic respiration and cancer cell death. HMGB1 is a member of the HMG protein family. It contains two DNA-binding HMG-box domains and an acidic C-terminal tail capable of positively or negatively modulating its biological properties. In this work, we report that the deletion of the C-terminal tail of HMGB1 increases its activity towards a large panel of cancer cells without affecting the viability of normal immortalized fibroblasts. Moreover, in silico analysis suggests that the truncated form of HMGB1 retains the capacity of the full-length protein to interact with PKM2. However, based on the capacity of the cells to circumvent oxidative phosphorylation inhibition, we were able to identify either a cytotoxic or cytostatic effect of the proteins. Together, our study provides new insights in the characterization of the anticancer activity of HMGB1.
Identifiants
pubmed: 35887213
pii: ijms23147865
doi: 10.3390/ijms23147865
pmc: PMC9319070
pii:
doi:
Substances chimiques
HMGB1 Protein
0
Isoenzymes
0
Pyruvate Kinase
EC 2.7.1.40
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Coordenação de Aperfeicoamento de Pessoal de Nível Superior
ID : 88881.171201/2018-01
Organisme : Agence Nationale de la Recherche
ID : ANR-LABX-011
Organisme : Agence Nationale de la Recherche
ID : CACSICE ANR-11-EQPX-0008
Références
Sci Signal. 2009 Nov 17;2(97):ra73
pubmed: 19920251
Methods. 1998 Mar;14(3):329-41
pubmed: 9571088
Proteomics. 2004 Sep;4(9):2696-706
pubmed: 15352244
FASEB J. 2006 Aug;20(10):1727-9
pubmed: 16807371
Anticancer Res. 1997 Jul-Aug;17(4B):3153-6
pubmed: 9329624
Mol Cell. 2013 Nov 7;52(3):340-52
pubmed: 24120661
AIDS. 2007 Jan 30;21(3):283-92
pubmed: 17255735
Cancer Res. 2010 Nov 1;70(21):8558-68
pubmed: 20959471
Pharmacol Ther. 2014 Mar;141(3):347-57
pubmed: 24220159
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Mol Med. 2003 Jan-Feb;9(1-2):37-45
pubmed: 12765338
Dis Esophagus. 2013 Sep-Oct;26(7):746-53
pubmed: 23317289
Biotechniques. 2011 Feb;50(2):98-115
pubmed: 21486251
Mol Med. 2012 Dec 20;18:1360-2
pubmed: 23073660
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncotarget. 2014 Sep 30;5(18):8202-10
pubmed: 24077665
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Int J Oncol. 2013 May;42(5):1644-53
pubmed: 23546019
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
J Mol Model. 2006 Feb;12(3):281-9
pubmed: 16240095
World J Gastroenterol. 2012 Aug 14;18(30):4037-43
pubmed: 22912555
Nature. 2019 Apr;568(7750):117-121
pubmed: 30814728
Protein Sci. 2006 Nov;15(11):2507-24
pubmed: 17075131
Nat Chem Biol. 2012 Oct;8(10):839-47
pubmed: 22922757
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W522-5
pubmed: 17488841
Biochem Biophys Res Commun. 2007 Aug 17;360(1):14-9
pubmed: 17585880
Clin Cancer Res. 2004 Aug 15;10(16):5604-13
pubmed: 15328203
Antioxid Redox Signal. 2014 Mar 1;20(7):1075-85
pubmed: 23373897
Eur J Biochem. 1999 Mar;260(3):692-700
pubmed: 10102997
J Biol Chem. 2013 Dec 6;288(49):35406-16
pubmed: 24142698
Biochemistry. 2003 Mar 11;42(9):2664-71
pubmed: 12614161
J Immunol Methods. 2004 Jun;289(1-2):211-23
pubmed: 15251426
Oncotarget. 2016 Jul 26;7(30):48155-48167
pubmed: 27340866
Nat Commun. 2016 Mar 07;7:10764
pubmed: 26948869
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
pubmed: 11517324
Anticancer Res. 2000 Nov-Dec;20(6D):5077-82
pubmed: 11326672
EMBO J. 2002 Dec 16;21(24):6865-73
pubmed: 12486007
J Exp Med. 2012 Aug 27;209(9):1519-28
pubmed: 22869893
J Biomed Sci. 2009 Sep 14;16:83
pubmed: 19751520
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
Nat Cell Biol. 2012 Dec;14(12):1295-304
pubmed: 23178880
Oncotarget. 2017 May 16;8(38):64534-64550
pubmed: 28969092
Semin Cell Dev Biol. 2015 Jul;43:43-51
pubmed: 26277545
Antioxidants (Basel). 2019 Jan 01;8(1):
pubmed: 30609656
Biochemistry. 1994 Dec 13;33(49):14690-5
pubmed: 7993897
Trends Biotechnol. 2014 Jan;32(1):54-60
pubmed: 24183828
Oncotarget. 2015 Jul 30;6(21):18518-33
pubmed: 26041882
Curr Pharm Des. 2016;22(44):6625-6644
pubmed: 27587198
Biochemistry. 2004 Sep 28;43(38):11992-7
pubmed: 15379539
Oncol Lett. 2016 Mar;11(3):1980-1986
pubmed: 26998110
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
PLoS One. 2013;8(2):e57610
pubmed: 23451252
Annu Rev Immunol. 2010;28:367-88
pubmed: 20192808
Cold Spring Harb Protoc. 2016 Apr 01;2016(4):pdb.prot087379
pubmed: 27037069
Immunol Cell Biol. 2013 Aug;91(7):443-50
pubmed: 23797067
Oncotarget. 2017 Jan 31;8(5):8854-8866
pubmed: 27750219
Front Cell Dev Biol. 2018 Jul 24;6:79
pubmed: 30087897
Protein Expr Purif. 2019 Oct;162:44-50
pubmed: 31145974
Biochemistry. 2004 Aug 3;43(30):9901-8
pubmed: 15274644
J Mol Biol. 2010 Nov 12;403(5):706-22
pubmed: 20691192
Biochemistry. 2001 Aug 28;40(34):10254-61
pubmed: 11513603
J Leukoc Biol. 2010 Nov;88(5):973-9
pubmed: 20682624
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609